Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tramadol + ketamine
- Development stage
- Unknown
- Lead developer
- Grünenthal
- Modality
- Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
A combination of tramadol and ketamine used for pain management. Tramadol is an opioid analgesic that acts as a μ-opioid receptor agonist and inhibits serotonin and norepinephrine reuptake. Ketamine is a non-competitive NMDA receptor antagonist. When combined, they provide synergistic analgesic effects, potentially reducing the need for higher doses of either medication alone and decreasing associated adverse effects.
02
Targets
NMDAR (Glutamate receptor ionotropic, NMDA)SERT (Sodium-dependent serotonin transporter)MOR (Mu opioid receptor)NET (Norepinephrine Transporter)
Beyond the preview
Go deeper on tramadol + ketamine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tramadol + ketamine.